Regenerative aesthetics is the name given to treatments that try to improve the skin’s own biology rather than add volume or take tissue away, and in 2026 the menu is dominated by three: PRP, made from your own blood; PDRN, purified from salmon DNA and sold under names like the salmon sperm facial; and exosomes, harvested from cultured cells. They are not equivalent to one another. One is established with modest, real effects. One has a genuine mechanism and a growing body of evidence. One has no approved product in the United States and an active trail of federal warning letters behind it. And none of the three acts at the depth where a face actually falls.
I am a facial surgeon, which is a conflict of interest in an article like this one, so let me put it on the table in the first hundred words instead of the last. I have a professional interest in you understanding the limits of nonsurgical treatment. That is exactly why every claim below is tied to published work I will name, and why I am going to be equally plain about the patients for whom these treatments are the right purchase and an operation would be the wrong one.
Why is regenerative aesthetics suddenly everywhere?
The trend is real and it is peaking. Trade coverage of the 2026 skincare year describes regenerative aesthetics moving out of the early-adopter corner and into ordinary practice, and the expert roundups written for this year name polynucleotides and PDRN among the ingredients that will define it. Consumer coverage has been running the salmon sperm headline since the summer of 2025, with dermatologists quoted in national outlets arguing about whether it is substance or novelty.
Two forces are driving this, and only one of them is scientific. After two decades of adding volume with filler, the field became more interested in improving the tissue itself, and that is a healthy correction that I welcome. The second force is commercial. Regenerative treatments are repeatable, they are sold in packages of sessions with maintenance attached, and they can be delivered by people who are not surgeons in rooms that are not operating rooms. A treatment that must be repeated indefinitely is a better business than an operation someone has once. That does not make it fraudulent. It does mean the incentives behind the marketing deserve your attention.
The three questions I ask about anything sold as regenerative
Before the products, the framework, because the framework will outlast this year’s trend cycle.
What does it physically do, and at what depth? Not what it supports or revitalizes or awakens. What tissue does it touch, and what does it change there. This question alone dissolves most of the category’s advertising.
What does human evidence show, as distinct from laboratory or animal evidence? Cells in a dish and rats in a study are how good science starts, not how it finishes. A great many regenerative claims cite a mechanism and let you assume the clinical result.
Where do regulators stand on the specific product? Not the category, not the research field. The product in the syringe. This is the question that separates the three items on this menu most sharply, and it is the one patients almost never ask.
PRP, and the asterisk every serious review puts on it
Platelet-rich plasma is made by drawing your blood, spinning it in a centrifuge to concentrate the platelets, and injecting that concentrate back into your skin. Because it comes from you, it sidesteps most of the regulatory and immunologic questions that surround the other two. The theory is that concentrated platelets release growth factors that stimulate collagen production and tissue repair.
The evidence is genuinely supportive and genuinely imperfect, and both halves matter. A 2024 review in Cureus, built on a systematic PRISMA search across thirteen studies, reported consistently positive outcomes including improvement in collagen density and overall skin appearance, alongside a favorable safety profile. A systematic review and meta-analysis of PRP around the eyes, covering nineteen studies and pooling three randomized controlled trials for patient satisfaction, found satisfaction significantly above controls, with histologic improvement in photoaging and blinded evaluators judging treated skin as rejuvenated. A third systematic review, in Plastic and Reconstructive Surgery, found that eleven of the twelve studies it identified, including three randomized split-face trials, showed improved results, and said in the same sentence that study designs and outcome measures differed and that many of those measures were subjective.
Now the asterisk, which every one of those reviews states directly. There is substantial heterogeneity in how PRP is prepared and how outcomes are measured. Different centrifuges, different spin protocols, different platelet concentrations, different activation methods, different injection depths, different scoring systems. The reviews ask, repeatedly, for standardized protocols and larger trials with longer follow-up. In plain language: PRP is not one thing. The PRP in a published study and the PRP in a given treatment room may be meaningfully different products, and nobody can tell you exactly how different.
So my position is not skeptical, it is bounded. PRP is a reasonable option if you want incremental improvement in skin texture and quality, you understand that incremental is the correct word, and you are prepared to repeat it. Ask specifically how your PRP is prepared and by whom. And be wary of any before-and-after taken a few days after treatment, when swelling from the injections is doing part of the work in the photograph.
Does the salmon sperm facial actually work?
The injected version has real evidence behind it. The version in the jar mostly borrows that evidence, and the distance between those two answers is the most useful thing in this section.
PDRN stands for polydeoxyribonucleotide. It is a purified preparation of DNA fragments, most often sourced from salmon sperm or trout roe, which is where the memorable marketing name comes from. You will also see the word polynucleotides, which describes closely related preparations and is often used interchangeably in clinics.
Let me correct one thing you will read almost everywhere, because it is the kind of half truth that makes a whole category sound more magical than it is. Salmon DNA is not used because it resembles your DNA in sequence, and any advertisement implying a percentage of similarity to your own genome is selling a coincidence of chemistry as though it were kinship. The building blocks of DNA are chemically the same across species, which is why a purified salmon fragment is biologically recognizable to human cells and, in reported use, well tolerated. That tolerance owes as much to the purification, which strips out the salmon proteins that would actually provoke a reaction, as it does to any structural resemblance. The fish is not the point. The purification is.
The mechanism itself is not hand waving. PDRN has been studied as acting through the adenosine A2A receptor, and a 2017 review in Frontiers in Pharmacology gathers the pharmacology and the early clinical use in one place. The animal work is specific: in one rat model of ischemic colitis, PDRN increased VEGF expression and suppressed inflammatory cytokines through that receptor. I cite that study as exactly what it is, a single preclinical example in an organ that is not skin, because the honest version of this argument does not need to pretend otherwise. A real receptor and a plausible repair pathway explain why the molecule attracted clinical interest in wound healing long before it became a beauty trend, and it arrived in aesthetics through Korean dermatology in clinic-administered injectable form, which is the version that built its reputation.
Here is the distinction consumer coverage blurs, and it is the single most useful thing I can tell you about this category. Injected PDRN carries the stronger clinical evidence, and it is worth being exact about how strong. A 2024 review in the International Journal of Molecular Sciences gathered the human aesthetic use of injectable polynucleotides and PDRN and found studies reporting improvement in skin texture, wrinkle depth, elasticity and hydration, including a randomized, double blind, split face trial in thirty participants where the polynucleotide side improved elasticity and texture more than a hyaluronic acid filler. The same review is candid that other studies found limited or no benefit, and it names its own ceiling: the field is short on large, high quality randomized trials and leans on observational studies, case reports and small pilot studies. That is encouraging evidence with an honest limit on it, which is a different thing from proof and a different thing from nothing.
Topical PDRN, meaning the serums and creams now sold everywhere, runs into physics. The researchers working on this problem state it plainly: PDRN fragments run to roughly fifty to fifteen hundred kilodaltons, while efficient passive permeation of intact skin is generally limited to molecules under about five hundred daltons. The molecule is orders of magnitude too large to simply diffuse across the stratum corneum, and its negative charge does not help. A needle crosses that barrier. An ordinary serum, largely, does not. There is real laboratory work underway to engineer around it, by shrinking and neutralizing the molecule so that it can pass, and that work may well succeed. It is also, quietly, the best available admission that the ordinary jar has a problem, because nobody engineers a solution to a barrier that was never there.
My read on PDRN, then. The mechanism is real, the injectable evidence is encouraging, the direction of the research is positive, and the reported safety profile has been reasonable. It sits in a defensible position on this menu. What it does not do is lift anything, and we are about to get to why.
Exosomes: the one where I stop being diplomatic
Exosomes are extracellular vesicles, tiny membrane-bound packages that cells release to communicate with one another, carrying proteins, lipids and RNA. As a research field this is legitimately exciting, and I want to be precise about my objection. It is not to the science. It is to the commerce that has run ahead of the science.
The regulatory picture in the United States is not ambiguous. There are no FDA-approved exosome products, for aesthetics or for anything else. The agency said so in a public safety notification and has not withdrawn it, and its language about the clinics selling these products anyway is not diplomatic either: it describes them as taking advantage of patients and flouting federal statutes and FDA regulations. Warning letters have followed. One sent to a manufacturer in December of 2024 and another in September of 2025 tell the companies the same thing in statutory language, that their products are unapproved new drugs and unlicensed biological products, and that distributing them is prohibited.
The trail runs in both directions, and I want you to know that too. In June of 2026 the agency closed out an earlier case after the manufacturer represented that it had stopped making and selling its exosome products and removed them from every sales channel, and a follow-up inspection found no evidence to the contrary. Enforcement that ends when the conduct ends is enforcement working properly. It is also the clearest possible evidence that the letters are not a formality.
The safety record is not theoretical either. That notification was issued in the first place because patients in Nebraska suffered serious adverse events after treatment with unapproved products marketed as containing exosomes, brought to the agency’s attention with the help of the CDC and the state health department. The best documented infection outbreaks in this broader field involve related unapproved cell and tissue products rather than exosomes specifically, and they are worth knowing about anyway: in 2018 the CDC described twenty patients across eight states who developed bloodstream and joint infections after receiving a bacterially contaminated umbilical cord blood-derived product. I include that case deliberately. It is the clearest available picture of what happens when a biological product reaches a patient without the manufacturing controls that approval exists to enforce.
And then there is the quieter problem, the one I find equally disqualifying at the clinical level. Verification. The international research community published a long set of minimum standards for characterizing extracellular vesicles, updated in 2024, precisely because even specialist laboratories find it difficult to establish what a preparation actually contains and whether it holds functional vesicles at a meaningful dose. If identity, purity, potency and dose cannot be established, then what is being sold is not a medicine with a known profile. It is a liquid with a story attached.
Two fair caveats, because accuracy matters more to me than rhetoric. The first is that the research itself is serious and active. A 2025 systematic review pooled eleven clinical studies of exosome therapy for hair loss, covering two hundred and ninety-eight patients, and found that every one of them reported improvement in at least one hair measure with no serious adverse events, while stating plainly that small samples, differing protocols and short follow-up mean larger and better trials are still needed. ClinicalTrials.gov lists hundreds of registered trials involving exosomes or extracellular vesicles across many conditions. This field may well produce approved products, and when it does my position will move with the evidence rather than against it. The second caveat is jurisdictional. The FDA governs the United States, and in Mexico the corresponding authority is COFEPRIS. I raise the FDA position not because it governs my operating room but because it is the most extensively documented public assessment of this product category that any patient can read, and because most of the people reading this are American. A product category that has not cleared a rigorous regulatory bar anywhere has not cleared it for you either, wherever you happen to be standing when it is offered.
So: I do not use exosome products, and I would advise a patient to decline them until an approved one exists. If a provider offers them, ask which specific product, what its regulatory status is, and whether it is being given as part of a registered trial with a number you can look up. A confident answer to all three is rare.
The audit, one card each
PRP
Platelet-rich plasma, spun from your own blood
- Depth
- Dermis, roughly one to three millimeters
- Human evidence
- Systematic reviews report real, modest improvement. Preparation and outcome measures vary widely.
- Regulators
- Made from you, so there is no approved-product question to answer.
PDRN
Purified DNA fragments, the salmon sperm facial
- Depth
- Dermis when injected. The stratum corneum when applied.
- Human evidence
- Encouraging for the injectable. The topical borrows credibility the jar has not earned.
- Regulators
- Varies by country and by preparation. Ask what you are being given.
Exosomes
Vesicles harvested from cultured cells
- Depth
- Same shallow territory, wherever it is placed.
- Human evidence
- An active research field. No approved product to attach the research to.
- Regulators
- No FDA-approved product. Warning letters to manufacturers and clinics.
Two of those three are worth taking seriously today. The third may be worth taking seriously later. What none of them is, and this is where the whole category quietly changes the subject, is a substitute for an operation.
Can any of it replace a facelift?
No, and this is the one place in the article where I am not going to hedge, because the answer is not a matter of clinical opinion. It is a matter of measurement, and here is the measurement.
Everything on the regenerative menu works in the top layers of your skin. Injections of PRP or PDRN sit in the dermis, roughly one to three millimeters below the surface. Topical products act at the stratum corneum, a fraction of a millimeter. Microneedling channels go a little deeper and stay in the same neighborhood. This is not a criticism. It is the design of the treatments. Skin quality lives there, and improving skin quality is what these products are built to do.
Facial descent does not live there. When the midface flattens, when jowls break the line of the jaw, when the neck loses its angle, the cause is not the quality of the skin. It is that deeper structures have moved: the Short, tough fibrous bands that tether the soft tissue of the face to the bone beneath it. They loosen with age, which is what allows the tissue they hold to slide downward. Releasing them is a surgical maneuver, not something a molecule does. that anchor facial soft tissue have loosened, the deep fat compartments have descended and deflated, and the whole soft tissue envelope has shifted down over the facial skeleton. The plane where that is corrected surgically sits well below the dermis, beneath the SMAS layer described by Mitz and Peyronie in 1976, in the deep plane approach Sam Hamra described in 1990.
I put this in a diagram because it is the kind of thing that becomes obvious the instant you see it drawn to scale and stays abstract forever if you only read about it.
0 to 3 mmSerums, microneedling, PRP, PDRN. The whole regenerative menu works in this band.
This distance is the argumentNot dosage. Not technique. Anatomy.
Around 8 mmThe SMAS, the fibrous sheet that carries the face.
Around 10 mmThe deep plane, beneath the SMAS, where descent is released and repositioned.
That distance is the whole argument. It is not a matter of dosage, or technique, or trying harder, or a better molecule arriving next year. It is anatomy. Improving the quality of a fabric does not change where the fabric hangs.
Once you can see the depth, the marketing decodes itself
A phrase like nonsurgical facelift describes a treatment that does not act at the depth where a facelift acts. Liquid lift, regenerative lift, biological lift, and the various device names that promise lifting from the outside are all doing the same work: borrowing the word for an operation and attaching it to something that is not one. Several of those treatments are perfectly good at what they actually do. None of them does what the word lift implies. I have written separately about where energy devices genuinely help and where they cannot reach, and about the ultrasound tightening claims that patients bring me most often.
I should be careful here, because it would be easy to read this article as a surgeon dismissing everything he does not perform, and that is not my position. My own practice uses radiofrequency microneedling, CO2 and other lasers, as complements at the time of surgery and as maintenance afterward, because an operation moves tissue and does not resurface it. Sun damage, texture and tone are real problems that a lift does not solve. The error is never using these tools. The error is using them instead of the thing your face actually needs, and then discovering two years and several packages later that the problem you were treating was never the problem you had.
The rhythm nobody puts in the brochure
There is a second structural difference between these categories, and this one is about time rather than depth.
A program you stay in
An initial series a few weeks apart, then maintenance at intervals for as long as you want the effect. Not a flaw. It follows directly from the mechanism, because a stimulated biological process runs its course and then you stimulate it again.
A result you obtain once
A single event with a long tail. Aging continues afterward, from a changed starting position rather than a paused one. Individual results vary.
I am not telling you which shape to prefer. Plenty of people choose the cyclical one for good reasons: they are not ready, they are not candidates, they want something reversible, or they simply prefer small steps taken slowly. What I am telling you is that the two shapes deserve an honest comparison, and that a consultation which presents an ongoing program as the alternative to a single operation, without ever naming the difference in cadence, has left out something you needed in order to decide.
Where do these treatments and surgery actually fit together?
A piece that only says no is a sales pitch wearing a lab coat, so here is the constructive half.
For the patient whose concern is skin quality rather than position, regenerative treatments may be exactly right and surgery exactly wrong. Fine lines, texture, dullness and early photoaging in someone whose facial structure is still well supported is not a surgical problem, and telling that person to have an operation would be a failure of judgment even if the operation went perfectly. Part of my job is telling people no, and it points in both directions.
For the surgical patient, skin quality and structural position are separate variables, each addressed on its own terms. A face can be repositioned beautifully and still have sun-damaged skin, because what an operation changes is where tissue sits, not what its surface looks like. Coordinating skin treatment with a surgical plan is reasonable and common, and the specifics of timing and sequence belong in a conversation about your tissue and your history rather than in a general article.
That third variable matters more than most consultations admit, and telling descent apart from deflation is often the single most useful thing that happens in a first appointment. A face that has lost volume and a face that has descended can look similar in a mirror and need completely different answers.
How do you read a regenerative advertisement?
Start with the questions, because a provider worth buying from answers all five without flinching. What exactly is in the syringe, and what is its approval status? At what depth is it placed, and what tissue does it affect? What does the human evidence show, and can you point me to it? How many sessions, at what interval, and for how long to maintain it? And the one that tells you most about the person answering: what will this specifically not change about my face?
Then read the advertisement itself. The tells are consistent enough to list.
- a provider who tells you, unprompted, which of your concerns their treatment will not touch
- the specific product named, with its regulatory status stated plainly
- results shown at months rather than days
- realistic language about degree and duration, including the word maintenance
- willingness to refer you to a surgeon when the problem is structural, and to tell a surgical candidate to wait when she is not ready
- the word lift attached to a treatment that does not reposition structure
- before-and-after photographs taken within days of an injection, when swelling flatters the result
- mechanism presented as outcome, meaning laboratory or animal findings offered as clinical proof
- exosome products offered without a straight answer about regulatory status
- package pricing pressure applied before anyone has evaluated your face
- evidence drawn from the injectable literature being used to sell you a jar
- a provider who offers only nonsurgical treatment telling you that you do not need surgery, which is a conclusion they are not positioned to reach neutrally
What sits on my own menu
I have spent this article auditing what other people sell, so here is my own list, itemized on the same three questions.
Exosomes, I do not offer, for the reasons above. PRP and PDRN I regard as legitimate tools for skin quality, with modest, real and repeatable effects, and I have no objection at all to a patient using them with clear expectations about which problem they are solving. Resurfacing and radiofrequency I do use, at the time of surgery and afterward, for the sun damage and texture that no lift corrects. And the operation I offer only to the faces where the problem is position.
That last item is the one that costs me money, so let me be concrete about it. When someone arrives with texture, tone and early lines rather than descent, the correct recommendation from me is not an operation, and I say so, and she leaves without booking anything. I hold the regenerative industry to the standard of not selling a category error. An operation sold to a patient whose problem was her skin is the identical error running the other way, and it is the more expensive one to discover.
Where the evidence runs out
Four things I cannot tell you, named here rather than left out so that the article sounds more finished than the science is.
I cannot tell you that the PRP in your provider’s centrifuge behaves like the PRP in the published studies, because until preparation is standardized nobody can say how far the two have drifted apart. I cannot tell you how long injected PDRN holds, because the aesthetic literature is young, mostly small, and thin on long follow-up, and I cannot promise that a serum will ever match the needle, because the work to get the molecule across skin is still in the laboratory rather than in the jar you can buy. I cannot tell you that exosomes will fail, only that no approved product exists today and that I am not willing to let a patient fund the experiment. And I cannot give you a number comparing any of this against surgery, because no rigorous head to head work exists, in part because the two are aimed at different problems and a fair trial would be difficult to design.
If someone offers you certainty on any of those four, they are running ahead of the evidence, whichever direction they happen to be pointing.
So which problem do you actually have?
The regenerative menu is not a scam and it is not a facelift. It is a set of treatments that work on the quality of your skin, at a depth measured in a few millimeters, on a cadence that repeats. Two of the three carry evidence worth taking seriously. The third has no approved product and an enforcement trail behind it, and my advice is to wait.
So the useful question was never which of them is best. It is which of two problems is yours. If it is the surface, this menu may genuinely hold something for you, and you should hear that from someone who does not sell it. If it is the position, then nothing placed in the top three millimeters is going to reach the ten where the problem actually lives, and repeating it more often does not change that arithmetic.
No trend answers that question, and neither does an article. It is answered by someone looking at your face and telling you which of the two they see, which is most of what happens in a first consultation. Be ready for the answer to be that what you need is not what you came in asking for.